Peptable

Comparison

MGF vs Tirzepatide

Function

While MGF is upregulated in muscle after mechanical overload, where it supports tissue repair and growth; recombinant forms are studied for regenerative and performance-enhancement effects22138, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.

Mechanism

While MGF works as a 24-amino-acid E-peptide splice variant of IGF-1 (IGF-1Ec) produced in mechanically stressed or damaged muscle that activates IGF1R and local anabolic pathways involved in muscle repair and hypertrophy22138144, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.

Receptor

MGF

Insulin-like growth factor 1 receptor (IGF1R) 134139

Tirzepatide

Glucose-dependent insulinotropic polypeptide receptor (GIPR) and GLP-1 receptor (GLP1R) 24

Organism or Origin

MGF

Endogenous human IGF-1 splice variant (IGF-1Ec) 2213897

Tirzepatide

Synthetic dual GIP/GLP-1 receptor agonist modeled on human incretin hormones2480

Gene

MGF

IGF1

Tirzepatide

Not assigned in the current dataset.

Summary

MGF and Tirzepatide are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: MGF is more often discussed in the realm of Musculoskeletal health, whereas Tirzepatide is more often associated with the realm of Metabolic and endocrine and Cardiovascular health. Their biological logic is quite different: MGF is a growth factor mimetic and a signaling modulator, whereas Tirzepatide is a receptor agonist and a hormone analog. MGF has a more natural endogenous origin, while Tirzepatide is closer to synthetic analog background and their development context also differs, with MGF in Preclinical development while Tirzepatide is approved. MGF takes the form of a linear peptide, whereas Tirzepatide is closer to a peptide conjugate, Tirzepatide incorporates lipidation and d-amino acid substitution features that are not part of MGF; while their sequence patterns also diverge, with MGF showing protein-mimetic sequence features and Tirzepatide showing alpha-helical domain features.

Sources

22Mechano growth factor - Wikipedia, https://en.wikipedia.org/wiki/Mechano_growth_factor
97IGF1 Gene - Insulin Like Growth Factor 1, https://www.genecards.org/cgi-bin/carddisp.pl?gene=IGF1
134Insulin-like growth factor 1 receptor - Wikipedia, https://en.wikipedia.org/wiki/Insulin-like_growth_factor_1_receptor
138A Splice Variant of IGF-1 within the Growth Plate | PLOS One, https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0076133
139IGF1 receptor signaling pathways, https://pubmed.ncbi.nlm.nih.gov/29535161/
144Insulin-like growth factor 1 - Wikipedia, https://en.wikipedia.org/wiki/Insulin-like_growth_factor_1
24Tirzepatide - a dual GIP and GLP-1 (GLP1) receptor agonist, https://gpnotebook.com/pages/diabetes-and-endocrinology/tirzepatide-a-dual-gip-and-glp-1-glp1-receptor-agonist
80GLP-1 Localisation and Proglucagon Gene Expression in ..., https://pmc.ncbi.nlm.nih.gov/articles/PMC6200298/